April 12, 2024

PRISM Market Moves on Friday: Crude Rises on Geopolitical Strain; Globe Life Recovers from Fraud Allegations; Arista, JP Morgan Chase Stumble

US equities are trading lower on Friday at midday after stocks finished mostly higher on Thursday. The S&P 500 is on track for a second-straight weekly decline, and the Nasdaq is headed for a third-straight weekly decline. Big tech is mostly lower, and other underperformers include banks, semis, airlines, healthcare tech, software, cruise lines, and… [Read More]
April 12, 2024

Granite Ridge Expands Revolving Credit Facility, Adding Liquidity to Support Growth

Granite Ridge Resources (NYSE: GRNT) has successfully expanded its revolving credit facility, completing its semi-annual borrowing base redetermination and entry into the third amendment to the Company’s existing credit agreement this week. Under the amended terms, Granite Ridge has increased its borrowing base from $275 million to $300 million, raised the aggregate elected commitments by… [Read More]
April 12, 2024

Market Turbulence: Safety Assets Soar Amid Geopolitical Uncertainty and Earnings Season Insights

As geopolitical tensions heighten and banks initiate earnings season, markets exhibited notable shifts. Stocks declined as investors flocked to safety assets like bonds, gold, and the dollar due to increasing geopolitical risks. Concurrently, oil prices surged in anticipation of potential conflicts involving Israel and Iran. In the stock market, a tumultuous week culminated with significant… [Read More]
3D Illustration of Human Urinary System Bladder
April 12, 2024

Positive Data for Protara Therapeutics in Bladder Cancer Trial

Protara Therapeutics (Nasdaq: TARA) has released positive data from its ongoing clinical program of TARA-002, the company’s investigational cell-based therapy, being evaluated in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC). TARA-002 is targeting NMIBC including Bacillus Calmette-Guérin (BCG)-Unresponsive, BCG-Experienced and BCG-Naïve patient populations. Protara expects to share preliminary results from a pre-planned risk-benefit analysis… [Read More]
Red blood cells in artery
April 12, 2024

Silence Therapeutics Advances Strong Candidate for Cholesterol Control

Silence Therapeutics (Nasdaq: SLN) has reported additional results from its APOLLO Phase 1 study of zerlasiran (SLN360) in subjects with baseline lipoprotein(a) (Lp(a)) levels at or over 150 nmol/L. The results were published in the peer-reviewed Journal of the American Medical Association. Zerlasiran is designed to lower the body’s production of Lp(a), a key genetic… [Read More]
April 12, 2024

NeuroOne Celebrates First Implant of OneRF™ Ablation Electrode at Top-Ranked Hospital

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has announced that doctors at a top-ranked US hospital have successfully performed the first implant of the company’s OneRF™ Ablation Evo® sEEG-RF electrode. NeuroOne’s OneRF™ Ablation system is a thin film stereoelectroencephalography (sEEG)-guided radiofrequency (RF) system and is designed for recording electrical activity and ablating nervous tissue using a… [Read More]
April 12, 2024

Prism Stocks making the biggest moves before the bell: JPMorgan, BlackRock, Globe Life and more

Here’s a look at the corporate players creating buzz in premarket trading: JPMorgan — Despite surpassing income forecasts and registering lower credit costs than forecasted, the bank’s shares fell by 2.4%. The underperformance was linked to the bank’s net interest income, a crucial benchmark for earnings from lending activities, which might fall short of analysts’… [Read More]
April 11, 2024

PRISM Market Moves on Thursday: Alpine Immune Soars on Acquisition News; Nike Upgraded; Globe Life Falls on Fraud Allegations

US equities are trading mostly higher on Thursday at midday after Wednesday’s sharp selloff on concerns about sticky inflation. Outperformers include IT services, homebuilders, semis, airlines, and telecoms. Big tech is also mostly higher. Banks, insurers, energy, autos, credit cards, pharma, managed care, and food are faring worse. Treasuries are mixed, the Dollar index is… [Read More]
April 11, 2024

ProPhase to Launch BE-Smart Esophageal Cancer Test in 2024

Next generation diagnostics company, ProPhase Labs (Nasdaq: PRPH), expects to launch its breakthrough BE-Smart test for esophageal adenocarcinoma (EAC) in the second half of 2024. BE-Smart leverages sophisticated proteomics to improve early detection of EAC and stratifies patients into low or high-risk groups with remarkable accuracy. EAC is among the deadliest cancers with no effective… [Read More]